NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Healthcare

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.

TSXV:NGEN - Post by User

NervGen Pharma Corp > NGENF to be top biotech of 2024. Clinical trial results leak

<< Previous

Bullboard Posts

Next >>

Comment by rdgeo44on Feb 02, 2024 7:32pm

408 Views

Post# 35860672

RE:NGENF to be top biotech of 2024. Clinical trial results leak

Apart from the nice bump in the share price today, thank you for posting this article. I almost feel guilty when i look at the SP as I have a more important reason for supporting this company, that is I am praying this drug will be the break through that MS sufferers have been waiting for. Even though the company isn't focusing on MS, hopefully there will be some benefits to be had. Thanks for keeping us informed Stargazer1, we need all the good news we can get these days. Have a great weekend & keep the faith. rdgeo

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant